Causes and Risk Factors

Primary Causes

• Severe aqueous‑deficient dry eye – most often due to autoimmune diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis).
• Vitamin A deficiency – impairs mucin production and goblet‑cell function, leading to xerophthalmia.
• Lacrimal gland hypofunction – congenital or acquired (e.g., after radiation therapy to the head/neck).
• Medication‑induced dryness – antihistamines, isotretinoin, certain antidepressants, and anticholinergics.
• Environmental exposure – low humidity, wind, air‑conditioning, or heating systems.

Risk Factors

• Female sex (autoimmune diseases are more prevalent).
• Age > 50 years (tear production naturally declines).
• Systemic autoimmune disorders (Sjögren’s, lupus, rheumatoid arthritis).
• History of ocular surface surgery (LASIK, cataract extraction) that disrupts nerves.
• Long‑term use of preservative‑containing eye drops.
• Living in arid climates or working in environments with high airflow.
• Malnutrition, especially vitamin A deficiency (< 10 µg/dL serum retinol).

Diagnosis

Diagnosing xerophthalmic keratopathy begins with a thorough history and ocular examination. The goal is to confirm chronic ocular surface dryness, assess corneal integrity, and identify underlying systemic disease.

History & Symptom Review

• Duration and pattern of eye discomfort.
• Medication list, systemic illnesses, nutritional status.
• Occupational/environmental exposures.

Clinical Examination

• Slit‑lamp biomicroscopy – visualizes epithelial irregularities, punctate staining, and stromal haze.
• Fluorescein and lissamine green staining – highlights areas of epithelial loss and mucin deficiency.
• Tear Break‑Up Time (TBUT) – a value < 5 seconds suggests tear film instability.
• Schirmer I test (without anesthesia) – measures aqueous tear production; < 5 mm in 5 min is considered abnormal.
• Ocular Surface Disease Index (OSDI) questionnaire – quantifies symptom severity.

Adjunctive Tests

• Meibography – assesses meibomian gland loss, useful when evaporative dry eye contributes.
• Punctal fluorescein dye disappearance test – evaluates tear drainage.
• Serum vitamin A level – indicated in patients from high‑risk regions or with malnutrition.
• Autoimmune panel – ANA, SS‑A/SS‑B antibodies if Sjögren’s is suspected.
• In‑vivo confocal microscopy – can detect early sub‑basal nerve plexus loss and epithelial cell changes.

Treatment Options

Treatment is multi‑modal, targeting the underlying dryness, protecting the cornea, and, when needed, surgically restoring surface integrity.

Lubrication & Tear Conservation

• Preservative‑free artificial tears – use 4–6 times daily; formulations containing hyaluronic acid or carboxymethylcellulose provide longer residence time.
• Therapeutic lubricating ointments – applied at night to maintain a moist film.
• Autologous serum eye drops – contain growth factors and vitamin A; 20 % dilution is common for moderate‑severe cases.
• Punctal plugs (silicone or collagen) – block drainage and increase tear volume.

Anti‑Inflammatory Therapy

• Topical cyclosporine A 0.05 % (Restasis) – improves tear production by modulating ocular surface inflammation.
• Lifitegrast 5 % ophthalmic solution (Xiidra) – reduces inflammatory cytokine activity.
• Short courses of topical corticosteroids (e.g., prednisolone acetate 1 %) for acute flares, tapered to avoid glaucoma or cataract risk.

Nutritional & Systemic Measures

• Vitamin A supplementation – 200,000 IU orally once a week for 2–3 weeks (WHO protocol) in deficiency‑related cases.
• Omega‑3 fatty acid oral supplements – 1–2 g EPA/DHA daily can improve meibomian gland quality.
• Systemic immunosuppressants (e.g., hydroxychloroquine, azathioprine) for underlying autoimmune disease, under rheumatology guidance.

Procedural Interventions

• Intense Pulsed Light (IPL) therapy – reduces abnormal eyelid vasculature and improves meibum flow.
• Bandage contact lenses – protect an ulcerated cornea and promote epithelial healing.
• Amniotic membrane transplantation – provides anti‑inflammatory and anti‑scarring support for advanced keratopathy.
• Superficial keratectomy or phototherapeutic keratectomy (PTK) – removes scar tissue when visual axis is involved.
• Corneal transplantation (penetrating or lamellar keratoplasty) – reserved for end‑stage disease with irreversible scarring.

Lifestyle & Environmental Modifications

• Humidifiers (30‑40 % relative humidity) at home and work.
• Avoid direct airflow from fans, air‑conditioners, or heating vents.
• Protect eyes with wrap‑around sunglasses outdoors.
• Follow the 20‑20‑20 rule during screen use (every 20 min look at something 20 ft away for 20 seconds).

Living with Xerophthalmic Keratopathy

Successful long‑term management hinges on routine care, self‑monitoring, and regular professional follow‑up.

Daily Management Checklist

1. Apply preservative‑free artificial tears at least four times daily; reapply after exposure to wind or screen work.
2. Use ointment before bedtime to keep the eye moist overnight.
3. Inspect eyes each morning for redness, discharge, or new visual changes; keep a symptom diary.
4. Clean eyelid margins gently with a warm compress and diluted baby shampoo or commercially available lid‑scrub once daily.
5. Maintain a balanced diet rich in leafy greens, carrots, and liver to ensure adequate vitamin A intake.
6. Schedule ophthalmology appointments every 3–6 months, or sooner if symptoms worsen.

Psychosocial Tips

• Join dry‑eye support groups (online or local) to share coping strategies.
• Inform coworkers or teachers about the need for periodic breaks and a humid workstation.
• Consider low‑vision aids (magnifiers, high‑contrast reading glasses) if visual acuity declines.

Prevention

While some risk factors (age, genetics) cannot be changed, many modifiable actions can lower the chance of developing xerophthalmic keratopathy.

• Early detection and treatment of chronic dry eye—see an eye‑care professional if you experience persistent irritation.
• Routine eye‑lid hygiene for individuals with blepharitis or meibomian gland dysfunction.
• Limit use of preservative‑containing drops; switch to preservative‑free brands for long‑term use.
• Maintain adequate systemic hydration (≥2 L water/day) and a diet rich in omega‑3s and vitamin A.
• Protect eyes from environmental extremes—use protective eyewear in dusty or windy conditions.
• Regularly review medication lists with your physician; request alternatives if a drug is known to cause severe dryness.

Complications

If xerophthalmic keratopathy is left untreated, the following complications may develop, some of which can lead to irreversible vision loss.

• Corneal ulceration – breakdown of the epithelium can become infected, leading to a painful ulcer.
• Corneal scarring (nebular or stromal opacity) – reduces visual acuity.
• Secondary bacterial, fungal, or viral keratitis – infection is more common on a compromised corneal surface.
• Melting keratitis (corneal stromal lysis) – rapid tissue loss that may require urgent surgical intervention.
• Symblepharon (adhesion of eyelid to eyeball) – can restrict eye movement and worsen exposure.
• Glaucoma or cataract formation – can result from prolonged topical steroid use.
• Permanent visual impairment – especially when central corneal opacity involves the visual axis.

When to Seek Emergency Care

References: Mayo Clinic. Dry eye syndrome. 2023; WHO. Global prevalence of vitamin A deficiency. 2022; CDC. Ocular health guidelines. 2021; NIH. Sjögren’s syndrome research. 2023; Cleveland Clinic. Corneal disease overview. 2024; Lancet Ophthalmology. Management of severe dry eye and keratopathy. 2023.